Transformative Fingertip Blood Collection Device Produces Lab-Quality Test Results
|
By LabMedica International staff writers Posted on 08 Dec 2023 |

The traditional process of "blood work" for patients typically involves a visit to a laboratory service center where a professional, such as a nurse or phlebotomist, draws blood from the patient's vein. Now, a new blood collection device is set to revolutionize this standard procedure by allowing blood testing in more accessible and convenient locations, offering advantages for patients, healthcare providers, and collection sites.
Becton, Dickinson and Company’s (BD, Franklin Lakes, NJ, USA) BD MiniDraw Capillary Blood Collection System is an innovative device that collects blood samples through a fingerstick, yielding laboratory-quality results for several common blood tests. Unlike the conventional venous blood draw, this system is less invasive, utilizing capillary blood from the patient's finger, which can be done by a trained healthcare worker without the need for a vein puncture by a phlebotomist. The device’s design enables the acquisition of lab-quality results from a smaller blood volume than what is typically required for venous collections. Moreover, it offers more convenience to patients by allowing blood collection at new venues, such as retail pharmacies, potentially enhancing the overall patient experience and revolutionizing diagnostic testing.
The use of the BD MiniDraw Collection System benefits patients by enabling them to have blood drawn in familiar places they frequently visit, like retail pharmacies or grocery stores. These locations often have extended operating hours and may be more conveniently located near their homes or workplaces. For these alternative collection sites, such as retail settings, the system not only complements existing health and wellness programs, like vaccine administration but also has the potential to increase foot traffic. Healthcare providers can benefit too, as capillary blood collection could be offered right in a physician's office without needing specialized phlebotomy staff. This ease and reduced invasiveness of the process might lead to improved patient compliance with blood testing, which is crucial for regular health assessments and could aid in the early detection and better management of chronic diseases.
BD has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD MiniDraw Collection System. This clearance covers low-volume blood collection for various tests, including lipid panels, select chemistry tests, and hemoglobin and hematocrit (H&H) testing, which are some of the most frequently requested laboratory tests. They are essential for diagnosing and monitoring various chronic conditions, from hypertension to high cholesterol. Looking ahead, BD aims to broaden the range of blood tests facilitated by the BD MiniDraw Collection System.
"Because the BD MiniDraw Collection System enables blood collection at non-traditional sites that may be more convenient—like your local pharmacy rather than a standalone lab—we can expand health equity and access, and make it easier for patients to get the blood tests they need both for preventative care and the management of chronic conditions," said Dave Hickey, executive vice president and president of Life Sciences for BD. "This innovation is our strategy and pipeline coming to life, and proof of our commitment to enabling diagnostics and care in alternate settings."
Related Links:
BD
Latest Pathology News
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Channels
Clinical Chemistry
view channel
Blood Test Detects More High-Risk Prostate Cancers Than PSA
Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. Prostate-specific antigen (PSA) testing... Read more
Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
Rapid and accurate differentiation of stroke types remains a persistent challenge in emergency medicine, particularly because early imaging can miss ischemic events that require time-sensitive intervention.... Read moreMolecular Diagnostics
view channel
Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
Selecting adjuvant chemotherapy for hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer remains challenging because current genomic assays mainly estimate recurrence risk rather than predict... Read more
RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Allograft rejection and chronic graft dysfunction remain major challenges in solid organ transplantation, requiring careful immunologic matching and long-term surveillance. Fragmented pre- and post-transplant... Read more
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








